---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-24-000250"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:12:17.569378+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Globus Medical Q3 net sales $625.7M (+63% YoY), raises FY24 revenue and EPS guidance

## Summary
- Worldwide net sales $625.7M, up 63.1% YoY, driven by NuVasive addition and higher spine/enabling tech sales.
- GAAP diluted EPS $0.38 (vs $0.01 in Q3 2023); non-GAAP diluted EPS $0.83 (vs $0.57, +45.2%).
- Non-GAAP adjusted EBITDA $193.7M, or 31.0% of net sales.
- Raised FY2024 guidance: revenue $2.49-$2.50B; non-GAAP diluted EPS $2.90-$3.00 (includes $0.09 change in treatment of IPR&D).
- Net cash from operations $203.7M; non-GAAP free cash flow $161.7M in Q3.

## SEC filing metadata
- accession: 0001562762-24-000250
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000156276224000250/0001562762-24-000250-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000156276224000250/gmed-20241105x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-24-000250
- JSON: https://secwatch.observer/filing/0001562762-24-000250.json
- Plain text: https://secwatch.observer/filing/0001562762-24-000250.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.